Corvus Pharmaceuticals (CRVS) logo

Corvus Pharmaceuticals (CRVS) stock

Immune medicines , market cap $844M

$9.67
-3.40%

Why is CRVS down?

Down 31% in 3 months while the S&P 500 fell 10%.

  • Its share count rose 11.7% in a year, so each share is a smaller slice of the company.

Sources: Price history, Nov 20, 2026; Quarterly reports, Sep 30, 2026

−1Long-term trend below a falling 200-day average

Tell me next time CRVS moves

Free account, no card. An optional alert when CRVS moves or its score changes.Pro, $1 for a first month. An optional alert when CRVS moves or its score changes.Pro, 7 days free with a card. An optional alert when CRVS moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on CRVS →The other side, the timeline, and its peers, for Pro members.
Quality Score
-2
Poor
In its industry
#143of 273
Checks firing
1of 14
Choppy
From 52-week high
-64.1%
under its best in a year

CRVS's Quality Score rose 1 point on Fri, Nov 20, to -2. It had its calmest day in a week.

Follow CRVS's trial news. Pro members can get an alert when Corvus Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when CRVS files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextMar 2027“…enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data anticipated in March 2027”Trial data · SEC filing · Nov 5

Key facts on CRVS

Key facts on CRVS
Holding it backA $64M loss wider than $15M a year earlier
Latest filing8-K, Nov 5 Reported its quarterly results

CRVS in the news

Fri Nov 6Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results SEC filing 4:02 PM ET · GlobeNewswire CRVS closed +8.3% that day.

What's next

Sat Dec 12: American Society of Hematology…Industry event · date confirmed.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

CRVS catalysts

Coming up

After its last 4 reports it closed +2.8% on average, higher 3 of 4 times.

3 more coming up, with sizes and sources, for Pro members.

What's next for CRVS, and how long its cash lasts

Next step the company has named

Mar 2027“Angel Pharmaceuticals completes enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data anticipated in March 2027”Trial data · SEC filing · Nov 5

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaPhase 3 · Recruiting · 150 people · main data estimated Nov 2027 · NCT06561048

3 more trials, 1 with data due this year, 3 more milestones and 31 filings, for Pro members.

Cash runway

The company says its cash lasts into second quarter 2028 (8-K, Nov 5).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Mar 13, 2026)
  • At-the-market share sales program (424B5, filed Mar 13, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

Chief Business Officer Jeffrey Arcara bought 4,500 shares on Nov 13. 2 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Richard Miller’s 4 filings and quotes.

Get an alert when CRVS files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How CRVS ranks in Biotech

CRVS is #143 of 273 by Quality Score.

How CRVS ranks in Biotech
RankStockQuality Score
143Corvus Pharmaceuticals (CRVS) logoCRVSCorvus Pharmaceuticals-2

More in Biotech

When does CRVS report earnings, and what happens after?

Expected to report Thu Mar 11, after the close (in 110 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What CRVS reported on Nov 5, 2026

The quarter

A loss of $0.22 a share, from $0.12.

“The increase in research and development expenses of $9.3 million was primarily due to higher clinical trial costs associated with the development of soquelitinib as well as an increase in personnel related costs.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

CRVS's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “Based on its current plans, Corvus expects its cash, cash equivalents and marketable securities to fund operations into the second quarter of 2028.”

From its results filing (SEC filing · Nov 5)

The numbers

Market value
$844M
today
Free cash flow
-$47.9M
last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on CRVS: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+6.6%+0.4%+8.3%
May 7Aug 6Nov 5
ReportedGapReaction5
days
Nov 5, 2026After close+9.5%+8.3%+9.2%
Aug 6, 2026After close-6.9%+0.4%+9.2%
May 7, 2026After close+1.5%+6.6%-6.4%

CRVS closed higher after 3 of its last 4 reports.

All 4 reports, and CRVS's Quality Score going into each

CRVS has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on CRVS, and all 14 on every stock.Get in free →See the top 3 →Start Pro

CRVS RSI on Nov 20: 39.6, below its 50-day and 200-day averages

Not scored

RSI 39.6, MACD below signal, below both averages. Not scored.

The deep dive on CRVS

6 more findings on CRVS, each with its source, for Pro members.

CRVS share count over time

Shares: 11.7% more than a year ago (to Sep 30).

Shares of CRVS outstanding, as filed
Shares
outstanding
As
of
84.4MNov 5, 2026
84.1MAug 6, 2026
84.1MMay 7, 2026
84MMar 12, 2026
Offerings, shelves, and splits of CRVS, from its filings
From its
filings
Filed
Set up an at-the-market program for up to $200M of shares, about 24% of its market valueMar 13, 2026
Registered shares for a later sale (S-3ASR)Mar 13, 2026
Priced a sale of sharesJan 23, 2026
Registered shares for a later sale (S-3)Aug 6, 2024

CRVS insider trades

2 insiders bought $301K across 5 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyJeffrey Arcara$34KChief Business Officerat $11.46 on Nov 11, filed Nov 13

All 5 insider filings on CRVS from the last six months, for Pro members.

All CRVS insider trades

CRVS's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold CRVS?

In ETFs: CRVS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

37 employeesSouth San Francisco, CAcorvuspharma.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on CRVS and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn CRVS's score around: 8 things
  • 6 more filings explained, a plain line each
  • 4 more things pulling CRVS's score down
BreakawayNov 13Jeffrey Arcara bought CRVS$34K at $11.46, filed Nov 13

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: CRVS's Quality Score is -2 (Poor), #143 of 273 in Biotech. Insiders bought $301K in the last 6 months (Form 4).

What does CRVS's Quality Score say?

CRVS scores -2 today, which Breakaway calls Poor. It is #143 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 31% in 3 months while the S&P 500 fell 10%. Shares: 11.7% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is CRVS's Quality Score?

CRVS scores -2 today, which Breakaway calls Poor (below zero). That is #143 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CRVS's -2.

Are insiders buying CRVS?

2 insiders bought $301K across 5 filings in the last 6 months. No open-⁠market sales on record. The newest is Jeffrey Arcara, Chief Business Officer, who bought $34K on Nov 11. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Corvus Pharmaceuticals: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.